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AUTHOR’S VIEW
SOD3 boosts T cell infiltration by normalizing the tumor endothelium and inducing 
laminin-α4
Lorena Carmona-Rodríguez, Diego Martínez-Rey, Emilia Mira, and Santos Mañes
Department of Immunology and Oncology, Centro Nacional De Biotecnología/CSIC, Madrid, Spain
ABSTRACT
The conversion of a non-T cell-inflamed into a T cell-inflamed tumor microenvironment (TME) is a key to 
sensitizing tumors to T-cell-based immunotherapies. Recent data show that the extracellular superoxide 
dismutase (SOD3) alters endothelial basement membrane (EC-BM) composition, providing permissive 
signals that enhance tumor infiltration by effector T cells.
Abbreviations : AJ, adherens junction; EC, endothelial cell; EC-BM, endothelial basement membrane; HIF, 
hypoxia-inducible factor; ICAM-1, intercellular adhesion molecule-1; LAMA4, laminin-α4; SOD3, super-
oxide dismutase-3; TME, tumor microenvironment; VCAM-1, vascular cell adhesion molecule-1; VEGF, 
vascular-endothelial growth factor
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The density of tumor-infiltrating T lymphocytes (TIL) determines 
patient prognosis and response to immunotherapy. Tumors 
nonetheless restrict T cell infiltration, and thus evade the immune 
system. T cell exclusion has been associated with activation of 
oncogenic pathways, inactivation of tumor suppressors, heigh-
tened production of certain inflammatory mediators, and accu-
mulation of the products of cancer cell metabolism.1 In addition 
to, or as a consequence of these cancer cell-intrinsic events, 
tumors actively alter the endothelium and that constitutes another 
factor that shapes the inflammatory infiltrate.
Leukocyte extravasation from the bloodstream into a tissue 
entails sequential adhesion steps regulated by adhesion receptors 
and chemokines that culminates in crossing of the endothelial cell 
(EC) layer. Adhesion receptors, common to all endothelia, are 
necessary for diapedesis of all leukocyte types. Downmodulation 
of the main EC adhesion molecules (ICAM-1 or VCAM-1) is 
a feature of tumors with “immune desertification”. Inflamed 
tumors can also fine-tune infiltration of effector and suppressor 
immune cells by modulating chemokine expression.2 To reach the 
tumor parenchyma, leukocytes must also cross the EC-BM, the 
main extracellular matrix structure that lies beneath EC.3 EC-BM 
constituents include type IV collagen, fibronectin, perlecan, nido-
gen, and laminins. Laminins are particularly interesting, since the 
laminin-α4 (LAMA4) subunit enhances, whereas laminin-α5 
(LAMA5) inhibits T cell diapedesis.3 How the TME influences EC- 
BM is not known precisely, although it can be predicted that tumor 
blood vessel abnormalities affect EC-BM composition and 
integrity.
Overexpression of angiogenic factors, such as the vascular- 
endothelial growth factor (VEGF), causes abnormal tumor 
vasculature, which is linked to T cell exclusion. Elevated per-
meability of the tumor vasculature impairs perfusion and 
increases interstitial pressure, both negative regulators of leu-
kocyte trafficking. Clinical evidence suggests that anti-VEGF 
agents synergize with immune checkpoint inhibitors to 
improve disease control and overall survival in different cancer 
types, an effect associated with larger numbers of effector 
T cells in the TME.4 Although an increase in TIL might be 
linked to transient normalization of the tumor vasculature, 
VEGF blockade can also create an immunodominant TME by 
impeding VEGF immunosuppressive activities.4 We reported 
that perivascular SOD3 triggers a program that simultaneously 
induces vascular normalization and T cell infiltration, thus 
linking these two processes unequivocally.5,6
The anti-oxidant enzyme SOD3 is usually downregulated in 
tumors, which suggests that its loss is advantageous for cancer 
progression.7 SOD3 catalyzes the dismutation of the superoxide 
radical (·O2−) in the extracellular space; this activity not only 
prevents oxidative damage of lipids or proteins but also pre-
serves the bioavailability of nitric oxide (NO). NO is essential for 
SOD3-induced vascular normalization due to its inhibitory 
activity on the prolyl hydroxylase domain protein (PHD)-2. 
The PHD are central regulators of the hypoxia-inducible tran-
scription factor (HIF)-α subunits, which they degrade in nor-
moxia. High SOD3 levels, but not those of a catalytically inactive 
mutant, stabilize HIF-2α (but not HIF-1α) in EC in a NO- 
dependent manner.5 This enhances HIF-2α-induced transcrip-
tion of vascular-endothelial cadherin (VEC; cadherin 5, CD144), 
responsible for assembly of endothelial adherens junctions (AJ) 
and barrier architecture. SOD3 thus reduces EC monolayer 
permeability, prevents VEGF-induced destabilization of AJ, 
improves tumor perfusion, and increases delivery of chemother-
apeutic drugs, all hallmarks of vessel normalization.5 Specific 
HIF-2α ablation in EC prevents SOD3-induced vascular normal-
ization in implanted tumors, which suggests that HIF-2α is 
a pivotal SOD3 mediator in vivo.5
Whereas postnatal ablation of PHD2 induces hyperactive 
angiogenesis due to HIF-1α stabilization, hemizygous PHD2 
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deletion in EC stabilizes HIF-2α, induces VEC expression, and 
normalizes tumor vasculature.8 NO also has antithetic, concen-
tration-dependent effects on endothelial barrier function.5 SOD3 
does not affect NO synthesis in EC but appears to establish 
a delicate NO/·O2− balance in the TME that promotes specific 
HIF-2α (but not HIF-1α) stabilization and EC barrier tightening.
The SOD3/HIF-2α axis also renders the tumor endothelium 
more permissive to T cell infiltration. In vitro, SOD3 over-
expression in EC increases transendothelial migration of 
naïve and activated CD4+ and CD8+ T cells, but not of myeloid 
(CD11b+) cells, in support of a specific EC-autonomous SOD3 
effect on T cell transmigration. In vivo, perivascular SOD3 
accumulation increases infiltration of adoptively transferred 
and endogenous tumor-specific T cells.6 Specific HIF-2α dele-
tion in the tumor endothelium causes a reduction in TIL 
numbers, which pinpoints HIF-2α as a necessary SOD3 med-
iator. SOD3 overexpression in the TME increases the CD8+/ 
FoxP3+ ratio compared to controls,6 which suggests distinct 
SOD3 effects on effector and regulatory T cell transmigration.
The mechanism by which the SOD3/HIF-2α pathway boosts 
T cell infiltration is independent of upregulation of endothelial 
adhesion receptors or T cell chemokines. HIF-2α instead upre-
gulates transcription of specific WNT ligands in EC, triggering 
WNT pathway activation.6 Pharmacological inhibition of the 
WNT pathway reverses the SOD3 effect on TIL infiltration 
in vitro and in vivo, which indicates its importance down-
stream of SOD3. A hallmark of WNT pathway activation is β- 
catenin stabilization. β-catenin levels are elevated in SOD3- 
overexpressing cells; however, β-catenin neither translocates 
to the nucleus nor induces transcription of canonical β- 
catenin-regulated genes in SOD3-overexpressing cells.6 It 
accumulates massively in the juxtamembrane area, probably 
due to β-catenin sequestration by VEC at AJ.
SOD3 induces nuclear accumulation of another WNT- 
induced transcription factor, FoxM1, whose deficiency causes 
vascular abnormalities.9 LAMA4, a permissive signal for T cell 
migration, is a transcriptional target of FoxM1.3 LAMA4 silen-
cing in EC abolishes SOD3-induced enhancement of T cell 
transmigration. In mouse tumor models, LAMA4 levels corre-
lated positively with TIL density after SOD3 overexpression; in 
contrast, LAMA4 and TIL were reduced after endothelial HIF- 
2α deletion or WNT pathway inhibition.6 These data support 
LAMA4 as a SOD3 mediator for TIL infiltration.
The SOD3/HIF-2α axis might operate in human malignancies. 
Indeed, SOD3 and VEC mRNA levels correlated positively in two 
colorectal cancer (CRC) cohorts, and most SOD3-stained tumor- 
associated EC showed HIF-2α staining.5 SOD3 levels correlate 
positively with CD8+ T cell infiltration in a stage II CRC cohort, 
and with a T-cell inflamed signature10 in the COAD cohort from 
TCGA. SOD3 levels are also associated with lower recurrence 
Figure 1. SOD3 ties vascular normalization to tumor infiltration by T cells. Specific SOD3-induced signaling pathways in tumor-associated EC. SOD3 is downregulated in 
most tumors (left). In this situation, NO is oxidized to form ·ONOO− and PHD enzymes are active, which fosters proteasomal-induced HIF-2α degradation; VEC expression 
is low, tumor interstitial pressure is high, and LAMA4 is reduced in the EC-BM, which hampers T cell infiltration. SOD3 re-expression in the TME (right) prevents ·NO 
oxidation, which inhibits PHD enzymes and stabilizes HIF-2α. HIF-2α then initiates a transcription program that upregulates VEC, reducing interstitial pressure, and 
induces specific WNT ligands, which triggers autocrine/paracrine activation of the WNT pathway. By stabilizing β-catenin, WNT signaling then strengthens AJ and 
simultaneously triggers LAMA4 upregulation through FoxM1; this generates a LAMA4-enriched EC-BM permissive for T cell infiltration.
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rates in the stage II cohort (follow-up 120 months),6 consistent 
with the prognostic value of CD8+ T cell infiltration in CRC.
These results identify a HIF-2α-dependent, SOD3-induced 
pathway that simultaneously triggers vascular normalization 
through VEC induction, and T cell infiltration through WNT 
pathway-induced LAMA4 expression (Figure 1). The SOD3 
downregulation observed in many human malignancies could 
be a mechanism for T cell desertification. Restoring SOD3 
levels in the TME might thus transform immunologically 
“cold” into T cell-inflamed tumors, rendering them more sus-
ceptible to T cell-based immunotherapies.
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